Salarius Pharmaceuticals Receives Second Installment of $1.7 Million in Payments from the Cancer Prevention and Research Institute ...
HOUSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced …